FIELD: medicine.
SUBSTANCE: 40-0-(2-hydroxiethyl)rapamycin is offered to apply in pharmaceutical formulation for inhibition and control of angiogenesis inadequate regulation or for related diseases. Specifically it is used for tumour treatment of brain, central nervous system, colon, rectum or reproductive system.
EFFECT: proliferation inhibition of vein endotheliocytes and proliferation inhibition stimulated by vascular endothelial growth factor.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| BIOMARKERS | 2005 |
|
RU2429297C2 |
| BIOMARKER | 2005 |
|
RU2385944C2 |
| STENTS WITH COATING CONTAINING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYL-AMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINAMIN | 2003 |
|
RU2341266C2 |
| NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
| RAPAMYCIN DERIVATIVE OR IMPDH INHIBITOR FOR TREATING POLYCYSTIC KIDNEY DISEASE | 2006 |
|
RU2491933C2 |
